Large‐vessel vasculitis induced by pegfilgrastim and immune checkpoint inhibitor in a patient with small‐cell lung cancer

Autor:	Keisuke Shiraha, Yuki Takigawa, Akiko Sato, Keiichi Fujiwara, Yuka Matsuo, Mayu Goda, Tomoyoshi Inoue, Eri Nakamura, Miho Fujiwara, Suzuka Matsuoka, Hiromi Watanabe, Kenichiro Kudo, Ken Sato, Takuo Shibayama
Jazyk:	angličtina
Rok vydání:	2024
Předmět:	immune checkpoint inhibitor immune‐related adverse event large‐vessel vasculitis pegfilgrastim small‐cell lung cancer Diseases of the respiratory system RC705-779
Zdroj:	Respirology Case Reports, Vol 12, Iss 2, Pp n/a-n/a (2024)
Druh dokumentu:	article
ISSN:	2051-3380
DOI:	10.1002/rcr2.1291
Popis:	Abstract A 75‐year‐old woman with stage IVB (cT3N3M1c) extensive disease small‐cell lung cancer was treated with carboplatin, etoposide, and atezolizumab. Ten days after pegfilgrastim initiation, during the second chemotherapy cycle, she experienced back pain. Contrast‐enhanced computed tomography revealed soft tissue thickening around the descending aorta and brachiocephalic artery. She was diagnosed with atezolizumab and pegfilgrastim‐induced large‐vessel vasculitis (LVV) and was treated with prednisolone, which was tapered and discontinued after 14 weeks, with no symptom recurrence. LVV should be included in the differential diagnosis of patients with nonspecific body pain when pegfilgrastim and immune checkpoint inhibitors are used in combination.
Databáze:	Directory of Open Access Journals
Externí odkaz:	https://doaj.org/article/dd241e56fcde4778a8abb4c9300c1ac0 Zobrazit plný text záznamu View record in DOAJ Plný text ve formátu PDF Plný text ve formátu HTML
Nepřihlášeným uživatelům se plný text nezobrazuje	K zobrazení výsledku je třeba se přihlásit.